Treatment with the investigational candidate SAGE-718 was generally well-tolerated and associated with cognitive improvements in people with Alzheimer’s disease, according to preliminary results from the LUMINARY Phase 2 clinical trial. The therapy’s developer, Sage Therapeutics, presented these findings in a talk, titled “SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer’s Disease: Results From the Phase 2 LUMINARY Study,” at the American Academy of Neurology’s 74th Annual Meeting. “Cognitive impairment is…
April 05, 2022April 5, 2022